Meningococcal Vaccines – Global Drug Forecast and Market Analysis to 2029
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Meningococcal disease is an infection caused by Neisseria meningitidis bacteria, and, although relatively rare, is widely feared because of its high mortality rate even in otherwise healthy individuals. Serogroups A, B, C, W, and Y are the most common meningococcal types in the nine major markets (9MM) covered in this report (US, France, Germany, Italy, Spain, UK, Argentina, Brazil, and China), and immunization of high-risk groups such as infants and adolescents provides the best protection against the infection. Immunization with conjugated meningococcal serogroup C (MenC) is routinely recommended for infants in the 5EU and Brazil, and immunization against serogroup ACWY (MenACWY vaccines) is recommended in the US, UK, Italy, and Spain for adolescents, and in Argentina for infants. In China, immunization with polysaccharide MenA and MenAC vaccines is routinely recommended for infants and young children.
Sanofi, GSK, and Pfizer are the major players in the meningococcal vaccine market, with GSK and Pfizer providing vaccines in each category, while Sanofi is offering only MenACWY vaccines. A major unmet need remains in a vaccine that combines the protection against all five serogroups most common in the 9MM.
Scope
- Overview of meningococcal disease, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
- Topline meningococcal vaccine market revenue from 2019–2029. Annual cost of immunization and major pipeline product sales in this forecast period are included.
- Key topics covered include current vaccination options, unmet needs and opportunities, and the drivers and barriers affecting meningococcal vaccine sales in the 9MM.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
- Analysis of the current and future market competition in the global meningococcal vaccine market. Insightful review of the key industry drivers, constraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Key Questions Answered
- How will the meningococcal vaccine market landscape in the 9MM (US, France, Germany, Italy, Spain, UK, Argentina, Brazil, China) change from 2019–2029?
- What are the most promising late-stage pipeline products for meningococcal vaccination?
- How do the clinical and commercial attributes of late-stage pipeline products compare with one another, and against existing immunization options?
- What are the remaining unmet needs in meningococcal immunization?
- What drivers and barriers will affect meningococcal vaccine sales in the 9MM over the forecast period?
Key Highlights
During the 10-year forecast period, there are two major pipeline products that are on track to launch, driving a forecast growth in the 9MM from $3.07b in 2019 to $3.17b in 2029, which represents a CAGR of 0.3%.
To combat the unmet need of a vaccine that combines protection against all five serogroups most common in the 9MM, both GSK and Pfizer are developing combination vaccines of their respective MenB and MenACWY vaccines that are projected to launch in the second half of the forecast period to 2029. The vaccine will also reduce the infant vaccine burden, while reducing the cost of vaccination and healthcare visits. The late-stage pipeline pentavalent MenABCWY vaccines are expected to gain a market share of 21% and sales of $670M in the 9MM by 2029. However, slow changing immunization recommendations and by targeting adolescent aged 10-25 years of age, leaves room for growth in the lucrative childhood immunization market in the 5EU, Brazil, Argentina, and China, if the companies seek approval for infants.
Reasons to Buy
The report will enable you to:
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global meningococcal vaccine market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the meningococcal vaccine market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Pfizer
Sanofi
CanSino Biologics
Beijing Tiantan Biological Products
Lanzhou Institute of Biological Products
Shanghai Institute of Biological Products
Shenzhen Sanofi Pasteur Biological Products
Walvax Biotechnology
Wuhan Institute of Biological Products
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.